Standard Standard

Impact on the phased abolition of co-payments on the utilisation of selected prescription medicines in Wales. / Alam, M.F.; Cohen, D.; Dunstan, Frank et al.
In: Health Economics, Vol. 27, No. 1, 01.2018, p. 236-243.

Research output: Contribution to journalArticlepeer-review

HarvardHarvard

Alam, MF, Cohen, D, Dunstan, F, Hughes, D & Routledge, PA 2018, 'Impact on the phased abolition of co-payments on the utilisation of selected prescription medicines in Wales', Health Economics, vol. 27, no. 1, pp. 236-243. https://doi.org/10.1002/hec.3530

APA

CBE

MLA

VancouverVancouver

Alam MF, Cohen D, Dunstan F, Hughes D, Routledge PA. Impact on the phased abolition of co-payments on the utilisation of selected prescription medicines in Wales. Health Economics. 2018 Jan;27(1):236-243. Epub 2017 Jul 7. doi: 10.1002/hec.3530

Author

Alam, M.F. ; Cohen, D. ; Dunstan, Frank et al. / Impact on the phased abolition of co-payments on the utilisation of selected prescription medicines in Wales. In: Health Economics. 2018 ; Vol. 27, No. 1. pp. 236-243.

RIS

TY - JOUR

T1 - Impact on the phased abolition of co-payments on the utilisation of selected prescription medicines in Wales

AU - Alam, M.F.

AU - Cohen, D.

AU - Dunstan, Frank

AU - Hughes, Dyfrig

AU - Routledge, P.A.

PY - 2018/1

Y1 - 2018/1

N2 - We have taken advantage of a natural experiment to measure the impact of the phased abolition of prescription co-payments in Wales. We investigated three study periods covering the phased abolition: from £6 to £4, £4 to £3 and £3 to £0. A difference-in-difference modelling was adopted and applied to monthly UK general practice level dispensing data on 14 selected medicines which had the highest percentage of items dispensed subject to a co-payment prior to abolition. Dispensing from a comparator region (North East of England) with similar health and socio-economic characteristics to Wales, and where prescription co-payments continued during the study periods, were used to isolate any non-price effects on dispensing in Wales. Results show a small increase in dispensing of 14 selected medicines versus the comparator. Compared with NE England, monthly average Welsh dispensing was increased by 11.93 items (7.67%; 95% CI: 7.2% to 8.1%), 6.37 items (3.38%; 95% CI: 2.9% to 3.7%) and 9.18 items (4.54%; 95% CI: 4.2% to 4.9%) per practice per 1000 population during the periods when co-payment was reduced. Price elasticities of the selected medicines utilisation were -0.23, -0.13 and -0.04 in three analyses, suggesting the abolition of co-payment had small effect on Welsh dispensing

AB - We have taken advantage of a natural experiment to measure the impact of the phased abolition of prescription co-payments in Wales. We investigated three study periods covering the phased abolition: from £6 to £4, £4 to £3 and £3 to £0. A difference-in-difference modelling was adopted and applied to monthly UK general practice level dispensing data on 14 selected medicines which had the highest percentage of items dispensed subject to a co-payment prior to abolition. Dispensing from a comparator region (North East of England) with similar health and socio-economic characteristics to Wales, and where prescription co-payments continued during the study periods, were used to isolate any non-price effects on dispensing in Wales. Results show a small increase in dispensing of 14 selected medicines versus the comparator. Compared with NE England, monthly average Welsh dispensing was increased by 11.93 items (7.67%; 95% CI: 7.2% to 8.1%), 6.37 items (3.38%; 95% CI: 2.9% to 3.7%) and 9.18 items (4.54%; 95% CI: 4.2% to 4.9%) per practice per 1000 population during the periods when co-payment was reduced. Price elasticities of the selected medicines utilisation were -0.23, -0.13 and -0.04 in three analyses, suggesting the abolition of co-payment had small effect on Welsh dispensing

U2 - 10.1002/hec.3530

DO - 10.1002/hec.3530

M3 - Article

VL - 27

SP - 236

EP - 243

JO - Health Economics

JF - Health Economics

SN - 1057-9230

IS - 1

ER -